Re:SARS-CoV-2 501Y.V2 escapes neutralization by South Africa...
by dnautics on Thursday January 21, 2021 @02:55PM
(#25863370)
> You have to repeat the full range of clinical trials with each reformulation that targets a new antigen.
Are you sure? I don't think we do this with the seasonal flu vaccine in general. It certainly wasn't a consideration in the CDC pandemic flu response fire drill (sequence antigen -> manufactured vaccine in ~2 weeks) that I got a sideline seat on.
I think you can't. It's famously difficult to anticipate off-target effects of any novel antigen target. This can't be tested in-vitro. You have to repeat the full range of clinical trials with each reformulation that targets a new antigen.